Campone Mario, Fumoleau Pierre
Service d'oncologie, Centre René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain Cedex.
Bull Cancer. 2002 Mar;89(3):275-82.
Clinical studies showed that paclitaxel is active as single agent and in combination chemotherapy for the management of metastatic breast cancer. A variety of doses and administration schedules have been evaluated in phase II and III trials. Weekly administration of paclitaxel which is generally well tolerated increases the therapeutic index (efficacy/safety) resulting from anti-angiogenic and pro-apoptotic effects.
